Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. [electronic resource]
Producer: 20071105Description: 4536-41 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab
- Carcinoma, Renal Cell -- drug therapy
- Disease-Free Survival
- Double-Blind Method
- Erlotinib Hydrochloride
- Female
- Humans
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Neoplasm Metastasis
- Placebos
- Quinazolines -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.